← Browse by Condition
Medical Condition

pathologic stage iia esophageal adenocarcinoma ajcc v8

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for pathologic stage iia esophageal adenocarcinoma ajcc v8 sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pathologic stage iia esophageal adenocarcinoma ajcc v8 Clinical Trials

How many clinical trials are currently recruiting for pathologic stage iia esophageal adenocarcinoma ajcc v8?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for pathologic stage iia esophageal adenocarcinoma ajcc v8, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pathologic stage iia esophageal adenocarcinoma ajcc v8?
pathologic stage iia esophageal adenocarcinoma ajcc v8 research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pathologic stage iia esophageal adenocarcinoma ajcc v8 clinical trial?
Eligibility criteria for pathologic stage iia esophageal adenocarcinoma ajcc v8 trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT04615013 Phase 1
Recruiting
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Enrollment
24 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

cervical esophagus adenocarcinoma (1) clinical stage ii esophageal adenocarcinoma ajcc v8 (1) clinical stage iia esophageal adenocarcinoma ajcc v8 (1) clinical stage iib esophageal adenocarcinoma ajcc v8 (1) clinical stage iii esophageal adenocarcinoma ajcc v8 (1) gastroesophageal junction adenocarcinoma (1) pathologic stage ii esophageal adenocarcinoma ajcc v8 (1) pathologic stage iib esophageal adenocarcinoma ajcc v8 (1) pathologic stage iii esophageal adenocarcinoma ajcc v8 (1) pathologic stage iiia esophageal adenocarcinoma ajcc v8 (1) pathologic stage iiib esophageal adenocarcinoma ajcc v8 (1) thoracic esophagus adenocarcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology